Matrixx Initiatives(MTXX) believes that its Zicam line of homeopathic cold remedies will relieve your cold symptoms. Jove Partners believes that it knows how to solve Matrixx’s own ailments: a sale of the company to a strategic investor. Jove filed a 13D today, disclosing a 5.1% ownership stake and declaring that The Reporting Persons appreciate the job that management… Read More »
Recently, Jove Partners disclosed a 5.2% stake in Lifetime Brands(LCUT). In its 13D filing, Jove reported that: The Reporting Persons believe that the Issuer would benefit from additional marketing and industry expertise on its board of directors, and have suggested individuals for consideration by the board. Lifetime CEO Jeffrey Siegel was quoted as saying “Jove Partners is a… Read More »
You may recall my December post regarding Nuvelo(NUVO). The company reported that a pivotal trial for its lead compound, alfimeprase, had failed to meet its endpoints. On the release of this news, the stock fell 80%, and has continued to float downwards since. Nuvelo began 2006 trading at $8.11 and quickly jumped above $17 when the company partnered… Read More »